Elixxer Ltd (ELXR) - Total Assets
Based on the latest financial reports, Elixxer Ltd (ELXR) holds total assets worth CA$2.17 Million CAD (≈ $1.57 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Elixxer Ltd (ELXR) net assets for net asset value and shareholders' equity analysis.
Elixxer Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Elixxer Ltd's total assets have evolved over time, based on quarterly financial data.
Elixxer Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Elixxer Ltd's total assets of CA$2.17 Million consist of 3.3% current assets and 96.7% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 1.0% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Elixxer Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Elixxer Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elixxer Ltd's current assets represent 3.3% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2024, down from 73.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Elixxer Ltd Competitors by Total Assets
Key competitors of Elixxer Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Elixxer Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.00 | 0.14 |
| Quick Ratio | 0.01 | 0.00 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-17.04 Million | CA$-14.44 Million | CA$-13.73 Million |
Elixxer Ltd - Advanced Valuation Insights
This section examines the relationship between Elixxer Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -24.0% |
| Total Assets | CA$2.13 Million |
| Market Capitalization | $328.10K USD |
Valuation Analysis
Below Book Valuation: The market values Elixxer Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Elixxer Ltd's assets decreased by 24.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Elixxer Ltd (2017–2024)
The table below shows the annual total assets of Elixxer Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$2.13 Million ≈ $1.54 Million |
-23.99% |
| 2023-12-31 | CA$2.81 Million ≈ $2.03 Million |
-47.69% |
| 2022-12-31 | CA$5.37 Million ≈ $3.88 Million |
-68.12% |
| 2021-12-31 | CA$16.84 Million ≈ $12.18 Million |
-19.11% |
| 2020-12-31 | CA$20.81 Million ≈ $15.06 Million |
+0.37% |
| 2018-12-31 | CA$20.74 Million ≈ $15.00 Million |
+654.85% |
| 2017-12-31 | CA$2.75 Million ≈ $1.99 Million |
-- |
About Elixxer Ltd
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Mon… Read more